{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:52:31Z","timestamp":1793321551628,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41401-021-00829-8","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T08:02:57Z","timestamp":1641283377000},"page":"2171-2172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor immunity: a novel dimension for PROTACs to conquer cancer?"],"prefix":"10.1038","volume":"43","author":[{"given":"Xuan-kun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"829_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, et al. Targeting public neoantigens for cancer immunotherapy. Nat Cancer. 2021;2:487\u201397.","journal-title":"Nat Cancer"},{"key":"829_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/cancers13010134","volume":"13","author":"A Mpakali","year":"2021","unstructured":"Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers. 2021;13:134.","journal-title":"Cancers"},{"key":"829_CR3","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","volume":"184","author":"SX Lu","year":"2021","unstructured":"Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184:4032\u201347.","journal-title":"Cell"},{"key":"829_CR4","doi-asserted-by":"crossref","unstructured":"Fidanza M, Gupta P, Sayana A, Shanker V, Pahlke S-M, Vu B, et al. Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma. Sci Transl Med. 2021;13:eaax4100.","DOI":"10.1126\/scitranslmed.aax4100"},{"key":"829_CR5","doi-asserted-by":"publisher","first-page":"eabd5515","DOI":"10.1126\/sciimmunol.abd5515","volume":"6","author":"J Douglass","year":"2021","unstructured":"Douglass J, Hsiue EH-C, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021;6:eabd5515.","journal-title":"Sci Immunol"},{"key":"829_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","volume":"6","author":"MJ Bond","year":"2020","unstructured":"Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs. ACS Cent Sci. 2020;6:1367\u201375.","journal-title":"ACS Cent Sci"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181:102\u201314.","journal-title":"Cell"},{"key":"829_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3389\/fimmu.2017.01920","volume":"8","author":"SC Moser","year":"2018","unstructured":"Moser SC, Voerman JS, Buckley DL, Winter GE, Schliehe C. Acute pharmacologic degradation of a stable antigen enhances its direct presentation on MHC class I molecules. Front Immunol. 2018;8:1920.","journal-title":"Front Immunol"},{"key":"829_CR9","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.3389\/fimmu.2018.02697","volume":"9","author":"SM Jensen","year":"2018","unstructured":"Jensen SM, Potts GK, Ready DB, Patterson MJ. Specific MHC-I peptides are induced using PROTACs. Front Immunol. 2018;9:2697.","journal-title":"Front Immunol"},{"key":"829_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4049\/jimmunol.2000252","volume":"207","author":"V Massafra","year":"2021","unstructured":"Massafra V, Tundo S, Dietzig A, Ducret A, Jost C, Klein C, et al. Proteolysis-targeting chimeras enhance T cell bispecific antibody-driven T cell activation and effector function through increased MHC class I antigen presentation in cancer cells. J Immunol. 2021;207:493\u2013504.","journal-title":"J Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00829-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00829-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00829-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:27:50Z","timestamp":1659338870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00829-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00829-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}